Natera's Signatera Gains Japan Approval for Colorectal Cancer Testing
Event summary
- Signatera received regulatory approval from Japan’s PMDA for colorectal cancer testing in the adjuvant setting.
- Natera expects to commercially launch Signatera for CRC in Japan by the end of 2026, subject to final pricing determination.
- More than 150,000 people are diagnosed with colorectal cancer in Japan each year.
- SRL, Inc., the largest reference lab in Japan, will support the commercialization of Signatera.
The big picture
Natera’s approval in Japan positions Signatera as a key player in personalized oncology, addressing a significant unmet need in colorectal cancer treatment. The backing from major medical societies and SRL’s extensive diagnostic network could drive rapid adoption, but success will hinge on pricing negotiations and clinician uptake.
What we're watching
- Market Penetration
- How quickly Natera can integrate Signatera into routine clinical practice in Japan through SRL’s extensive network.
- Regulatory Momentum
- Whether this approval accelerates Natera’s plans for additional cancer type submissions in Japan, such as muscle-invasive bladder cancer.
- Competitive Dynamics
- The pace at which competitors respond to Signatera’s entry into the Japanese market with their own MRD testing solutions.
Related topics